Article

Sublingual immunotherapy for hazelnut food allergy: a follow-up study.

Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology (impact factor: 2.83). 04/2008; 100(3):283-4. DOI:10.1016/S1081-1206(10)60456-5 pp.283-4
Source: PubMed
0 0
 · 
1 Bookmark
 · 
39 Views
  • Source
    Article: Hazelnut allergy: a multi-faced condition with demographic and geographic characteristics.
    D G Ebo, M M Verweij, V Sabato, M M Hagendorens, C H Bridts, L S De Clerck
    [show abstract] [hide abstract]
    ABSTRACT: Hazelnut (Corylus avellana) allergy varies from rather mild oral allergy symptoms to potentially life-threatening anaphylaxis and exhibits geographic and age-related variations. Severity of symptoms depends on the sensitisation profile of the patient and can partially be predicted using 'component-resolved diagnosis'. In our region (young) children predominantly exhibit sensitisation to hazelnut storage proteins Cor a 9 and Cor a 11 that is unrelated to birch pollen allergy and is generally associated with a more severe clinical outcome on consumption on raw and processed hazelnut. In contrast, adults predominantly present with an oral allergy syndrome due to an extensive cross-reactivity between the labile Cor a 1.04 and Bet v 1, the major allergen from birch (Betula verrucosa) pollen. In the absence of a cure, avoidance remains the key measure of effective management, particularly in those patients presenting with a severe form.
    Acta clinica Belgica 67(5):317-21. · 0.59 Impact Factor
  • Source
    Article: Food allergy: recent advances in pathophysiology and treatment.
    Julie Wang, Hugh A Sampson
    [show abstract] [hide abstract]
    ABSTRACT: Food allergies are adverse immune reactions to food proteins that affect up to 6% of children and 3-4% of adults. A wide range of symptoms can occur depending on whether IgE or non-IgE mediated mechanism are involved. Many factors influence the development of oral tolerance, including route of exposure, genetics, age of the host, and allergen factors. Advances have been made in the understanding of how these factors interact in the pathophysiology of food allergy. Currently, the mainstay of treatment for food allergies is avoidance and ready access to emergency medications. However, with the improved understanding of tolerance and advances in characterization of food allergens, several therapeutic strategies have been developed and are currently being investigated as potential treatments and/or cures for food allergy.
    Allergy, asthma & immunology research 10/2009; 1(1):19-29. · 1.91 Impact Factor
  • Source
    Article: FAST: Towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies.
    Laurian Zuidmeer-Jongejan, Montserrat Fernandez-Rivas, Lars K Poulsen, Angela Neubauer, Juan Asturias, Lars Blom, Joyce Boye, Carsten Bindslev-Jensen, Michael Clausen, Rosa Ferrara, [......], Heidi J Schnoor, Sigurveig Sigursdottir, Georg Stavroulakis, Frank Stolz, Ines Swoboda, Rudolf Valenta, Rob van den Hout, Serge A Versteeg, Marianne Witten, Ronald van Ree
    [show abstract] [hide abstract]
    ABSTRACT: The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment of food allergies, targeting prevalent, persistent and severe allergy to fish and peach. Classical allergen-specific immunotherapy (SIT), using subcutaneous injections with aqueous food extracts may be effective but has proven to be accompanied by too many anaphylactic side-effects. FAST aims to develop a safe alternative by replacing food extracts with hypoallergenic recombinant major allergens as the active ingredients of SIT. Both severe fish and peach allergy are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3), respectively. Two approaches are being evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and chemical modification. The most promising hypoallergens will be produced under GMP conditions. After pre-clinical testing (toxicology testing and efficacy in mouse models), SCIT with alum-absorbed hypoallergens will be evaluated in phase I/IIa and IIb randomized double-blind placebo-controlled (DBPC) clinical trials, with the DBPC food challenge as primary read-out. To understand the underlying immune mechanisms in depth serological and cellular immune analyses will be performed, allowing identification of novel biomarkers for monitoring treatment efficacy. FAST aims at improving the quality of life of food allergic patients by providing a safe and effective treatment that will significantly lower their threshold for fish or peach intake, thereby decreasing their anxiety and dependence on rescue medication.
    Clinical and translational allergy. 03/2012; 2(1):5.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.